---
title: Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
nct_id: NCT00327353
overall_status: COMPLETED
phase: PHASE4
sponsor: GlaxoSmithKline
study_type: INTERVENTIONAL
primary_condition: Asthma
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00327353.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00327353"
ct_last_update_post_date: 2009-05-22
last_seen_at: "2026-05-12T07:11:31.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol

**Official Title:** Single-Centre Randomised Open Crossover Study to Examine the Influence of Different Internal Resistances of Discus and Turbohaler Respectively on the Effects of Salmeterol and Formoterol in Asthmatic Subjects

**NCT ID:** [NCT00327353](https://clinicaltrials.gov/study/NCT00327353)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 77
- **Lead Sponsor:** GlaxoSmithKline
- **Conditions:** Asthma
- **Start Date:** 2004-01
- **CT.gov Last Update:** 2009-05-22

## Brief Summary

Effect of inhaled drugs administered as dry powder is not only dependent on drug efficacy but also on technical properties of the inhalers. Different inhalers have different internal resistances and therefore it is expected that patients with limited airflow may have different exposure rates of drugs delivered from different devices

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* Asthma Reversibility \>15% and 200 ml in total FEV1 \<85% of normal

Exclusion criteria:

* Smoking history \>20 pack years Treatment with ICS \>500μg Fluticasone or aquivalent in the last 4 weeks Asthma exacerbation in the last 4 weeks
```

## Interventions

- **formoterol (TURBOHALER)** (DRUG)
- **Salmeterol (DISKUS)** (DRUG)

## Primary Outcomes

- **Forced expiratory volume in 1 second (FEV1) under time curve 0.5-6 hours after inhalation of study medication**

## Secondary Outcomes

- **Airway resistances and peak FEV1 measured 0.5, 1, 2, 4 and 6 hours after inhalation of study drug**

## Locations (2)

- GSK Investigational Site, Gauting, Bavaria, Germany
- GSK Investigational Site, Berlin, State of Berlin, Germany

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.gsk investigational site|gauting|bavaria|germany` — added _(2026-05-12)_
- `locations.gsk investigational site|berlin|state of berlin|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00327353.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00327353*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*